Fig. 2: Sensitivity of SARS-CoV-2 D614G, B.1.1.7 and B.1.351 variants to sera from convalescent individuals.
From: Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
a, Examples of neutralization curves with sera from two donors (D18 and D59). The first donor, from the Orléans cohort, was sequentially sampled at months 3 (M3) and 6 (M6; left and middle, respectively). The second donor, from the Strasbourg cohort, was sampled at month 9 (M9; right). Results are shown as the mean ± s.d. from three independent experiments. b, ED50 of neutralization of the three viral isolates. Sera from the Orléans cohort were sequentially sampled at M3 (n = 28) and M6 (n = 25; left and middle, respectively), and 30 sera from the Strasbourg cohort were sampled at M9 (right). Data are the mean from two to four independent experiments. The dotted line indicates the limit of detection (ED50 = 30). Two-sided Friedman test with Dunn’s test for multiple comparisons was performed between each viral strain at the different time points; **P < 0.01, ***P < 0.001, ****P < 0.0001. M3: D614G versus B.1.351, P = 0.0012; B.1.1.7 versus B.1.351, P = 0.0012. M6: D614G versus B.1.351, P = 0.0005; B.1.1.7 versus B.1.351, P < 0.0001. M9: D614G versus B.1.351, P < 0.0001; B.1.1.7 versus B.1.351, P < 0.0001. c, Each individual was arbitrarily defined as a ‘neutralizer’ (blue) if neutralizing activity was detected at the first serum dilution (1:30) or ‘non-neutralizer’ (gray) if no activity was detected. The numbers indicate the percentage of neutralizers.
